Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An improved assay of cyclic 3',5'-nucleotide phosphodiesterases with QAE-Sephadex columns.

Literature DB >> 6247661

An improved assay of cyclic 3',5'-nucleotide phosphodiesterases with QAE-Sephadex columns.

Abstract

A method for the assay of cyclic nucleotide phosphodiesterases is described which employs chromatographical separation of cyclic nucleotides and nucleosides on QAE A-25 Sephadex columns and 5'-nucleotidase as an auxiliary enzyme. The assay allows quantitative recovery of adenosine, guanosine and their metabolites from the anion exchanger and thus is suitable for use in crude phosphodiesterase preparations containing purine catabolizing enzymes. In comparative studies, this method was found to be considerably more sensitive than previous reported methods because of lower assay blanks and higher recoveries of the nucleoside catabolites. The method is suitable for kinetic analysis of crude enzyme preparations from micromolar to millimolar substrate concentrations.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1980 PMID： 6247661 DOI： 10.1007/bf00510259

Source DB: PubMed Journal: Naunyn Schmiedebergs Arch Pharmacol ISSN： 0028-1298 Impact factor: 3.000

17 in total

1. A modified assay of 3':5'-cyclic-AMP phosphodiesterase.

Authors: R J Boudreau; G I Drummond
Journal: Anal Biochem Date: 1975-02 Impact factor: 3.365

2. Underestimation of cyclic 3',5'-nucleotide phosphodiesterase activity by a radioisotopic assay using an anionic-exchange resin.

Authors: T J Lynch; W Y Cheung
Journal: Anal Biochem Date: 1975-07 Impact factor: 3.365

3. Cyclic nucleotide phosphodiesterase activities of pig coronary arteries.

Authors: J N Wells; C E Baird; Y J Hardman; J G Wu
Journal: Biochim Biophys Acta Date: 1975-04-19

4. Assay for adenylate cyclase and cyclic nucleotide phosphodiesterases and the preparation of high specific activity 32-P-labeled substrates.

Authors: C Nakai; G Brooker
Journal: Biochim Biophys Acta Date: 1975-05-23

5. A rapid batch assay for cyclic AMP phosphodiesterase.

Authors: D R Zusman
Journal: Anal Biochem Date: 1978-02 Impact factor: 3.365

6. Activation and inhibition of lipolysis in isolated fat cells by various inhibitors of cyclic AMP phosphodiesterase.

Authors: U Schwabe; S Berndt; R Ebert
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1972 Impact factor: 3.000

7. An isotopic assay of cyclic 3',5'-nucleotide phosphodiesterase with aluminum oxide columns.

Authors: C R Filburn; J Karn
Journal: Anal Biochem Date: 1973-04 Impact factor: 3.365

8. A simple direct assay of 3',5'-cyclic nucleotide phosphodiesterase activity based on the use of polyacrylamide-bononate affinity gel chromatography.

Authors: C W Davis; J W Daly
Journal: J Cyclic Nucleotide Res Date: 1979

9. A comparison of the antilipolytic effects of nicotinic acid, methylisoxazole carboxylic acid, methylpyrazole carboxylic acid and insulin in isolated fat cells.

Authors: K Mengel; P B Meyer; R Ebert; U Schwabe
Journal: Pharmacology Date: 1972 Impact factor: 2.547

10. An effect of insulin on adipose-tissue adenosine 3':5'-cyclic monophosphate phosphodiesterase.

Authors: E G Loten; J G Sneyd
Journal: Biochem J Date: 1970-11 Impact factor: 3.857

28 in total

1. Effects of 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac preparations.

Authors: H von der Leyen; W Schmitz; H Scholz; J Scholz; M J Lohse; U Schwabe
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1989-08 Impact factor: 3.000

2. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors.

Authors: M J Lohse; K N Klotz; J Lindenborn-Fotinos; M Reddington; U Schwabe; R A Olsson
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1987-08 Impact factor: 3.000

3. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation.

Authors: K H Banner; E Moriggi; B Da Ros; G Schioppacassi; C Semeraro; C P Page
Journal: Br J Pharmacol Date: 1996-11 Impact factor: 8.739

4. Actions of the phosphodiesterase inhibitor zardaverine on guinea-pig ventricular muscle.

Authors: M Galvan; C Schudt
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1990-08 Impact factor: 3.000

5. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.

Authors: H von der Leyen; U Mende; W Meyer; J Neumann; M Nose; W Schmitz; H Scholz; J Starbatty; B Stein; H Wenzlaff
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1991-07 Impact factor: 3.000

6. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai.

Authors: C Schudt; S Winder; S Forderkunz; A Hatzelmann; V Ullrich
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1991-12 Impact factor: 3.000

7. Negative inotropic effect of vanadate in ventricular myocardium in the presence of 3-isobutyl-1-methylxanthine or isoprenaline.

Authors: R Brückner; W Schmitz; H Scholz; A Schumacher; E Erdmann; W Krawietz; K Werdan
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1980 Impact factor: 3.000

8. Adenosine and adenosine analogs inhibit phosphodiesterase activity in the heart.

Authors: W Meyer; M Nose; W Schmitz; H Scholz
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1984-12 Impact factor: 3.000

9. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.

Authors: H Tenor; A Hatzelmann; M K Church; C Schudt; J K Shute
Journal: Br J Pharmacol Date: 1996-08 Impact factor: 8.739

10. Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts.

Authors: T Bethke; W Meyer; W Schmitz; H Scholz; B Stein; K Thomas; H Wenzlaff
Journal: Br J Pharmacol Date: 1992-09 Impact factor: 8.739